EMA Authorised: Repaglinide Krka (repaglinide) — Krka, d.d., Novo mesto

View source ↗

Summary

The EMA authorised Repaglinide Krka for Type 2 diabetes mellitus. The product is a generic repaglinide from Krka, d.d., Novo mesto.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Repaglinide Krka (repaglinide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Krka, d.d., Novo mesto. Decision date: 03/02/2025